Introduction: Low-dose Aspirin is widely used for the prevention of cardiovascular events, but despite its beneficial effects, it can generate more or less serious digestive disorders. The aim of this study was to evaluate endoscopically by the Lanza score the gastroduodenal lesions in patients on long-term low-dose aspirin with upper gastrointestinal bleeding (UGB). Materials and Methods: A five years long prospective, descriptive study recruiting from the UGB patients admitted successively to the emergency department of a university hospital, those who were taking long-term low-dose aspirin (75-325mg/day). Eligible patients were those with UGB (hematemesis or melena) who had an esophagogastroduodenoscopy (OGD) within 24 hours following the bleeding. Results: Among 2135 cases of UGB admitted to emergency departments in the same period; 134 cases (6.3%) occurred in patients with low-dose aspirin with average age: 65.3 ± 24.7 years and sex ratio: 2.3 F / M. Hypertensive heart disease is noted in 123/134 (91.8%), Tobacco use in 32/134 (23.9%), alcohol in 28/134 (20.9%), concomitant NSAID therapy in 10/134 (7.5%), Anticoagulant in 20/134 (15%), and a history of peptic ulcer in 17/134 (12.7%). The UGB was severe in 73/134 (54.5%) and required blood transfusion in 89/134 (66.4%). At endoscopic examination: bulbar ulcer in 44/134 (32.9%), antral ulcer in 39/134 (29%) and erosive Bulbar duodenitis in 29/134 (21.6%). Stages 3 and 4 of the Lanza classification were observed in 95/134 (71%). All patients received anti-secretory medical treatment, endoscopic sclerosis was required in 6/134 (4.5%) and surgery in 3/134 (2.2%). Conclusion: In this work, women over 65 are the most concerned. Bulbar and antral ulcers are the most frequent lesions, and stages 3 and 4 are the most frequent of the Lanza score, these are evidence of the seriousness of the lesions caused by the long-term low-dose aspirin.
INTRODUCTION
Antiplatelet agent therapy with low-dose aspirin (75-325 mg) reduces vascular risk in patients with coronary heart disease. However, the use of aspirin even in low doses can lead to more or less serious digestive side effects, notably the occurrence of upper gastrointestinal bleeding (UGB). Still, many studies have shown other concomitant risk factors of gastrointestinal bleeding in these patients such as advanced age, alcohol consumption and smoking habits and concomitant use of nonsteroidal synthetic anti-inflammatory drugs (NSAID). The aim of this work is to share these risk factors in patients with low-dose aspirin for prevention of vascular accidents who are presenting upper gastrointestinal bleeding and to evaluate by endoscopy the mucosal lesions using the Lanza score. 
METHODS
It's a prospective, descriptive study recruiting from the UGB patients admitted successively to the emergency department of the Ibn Sina Hospital of Rabat Morocco for upper gastrointestinal bleeding (UGB), those who were taking low-dose aspirin (75-325mg / day) for the prevention of cardiovascular accidents. The duration of the study: 5 years. Upper gastrointestinal bleeding (UGB) is defined as hematemesis or melena. All patients are hospitalized in emergency departments and benefit from a structured interview conducted by the endoscopist on call specifying: age; Sex, past history of peptic ulcer or UGB, the nature of the heart disease, alcohol consumption and smoking habits, concomitant use of NSAID or anticoagulant, the used aspirin dose, duration of treatment, The abundance of the UGB and the other digestive signs. The clinical examination evaluates the hemodynamic conditions then an Intravenous is done, and a Hematocrit blood testing is performed. After the correction of the hemodynamic status and possible blood transfusion if necessary, an esophagogastroduodenoscopy (OGD) is performed in less than 24 hours. The description of the endoscopic lesions is done according to the Lanza classification: Stage 0: normal mucosa, Stage 1: hemorrhage or erosion, Stage 2: two to 10 hemorrhages or erosions, Stage 3: eleven to 25 hemorrhages or erosions, Stage 4: More than 25 hemorrhages or erosions or an ulcer regardless of its size. The various treatments introduced are specified: blood transfusion; anti-secretory medical treatment; endoscopic treatments of hemostasis (sclerosis); surgical treatment. The evolution of the patients is also specified.
RESULTS
During the study period, 2135 cases of UGB were successively admitted to the emergency department, 134 of which occurred in patients with low-dose aspirin for the prevention of cardiovascular accidents. The average age is 65.3±24.7; Female gender is predominant with a sex ratio of : 2.3 F /M. Clinical signs ( 
DISCUSSION
The efficacy of low-dose aspirin in the prevention of cardiovascular and cerebral thrombotic disease is well established (1) . Given the aging of the population and the frequency of the vascular pathology, an increasing number of patients receive this treatment over the long term. Despite the low doses used, epidemiological studies have demonstrated the persistence of a nonnegligible digestive toxicity of aspirin (2, 3) . Currently, the recommended doses for the prevention of thrombotic vascular diseases are 75 to 325 mg / d (1) . It is well established that aspirin has dose-dependent digestive toxicity. The hope of being able to prescribe low doses retaining an anti-aggregating effect and devoid of digestive toxicity did not materialize. Studies in the healthy volunteer showed that doses of aspirin lower than 100 mg caused gastroduodenal mucosa lesions and blood loss measurable by the gastric lavage technique (4) . Cryer and Feldman (5) evaluated in 10 healthy volunteers the gastroduodenal tolerance of aspirin given for three months at the 10 mg/day dosage. This dose was sufficient to reduce the pool of prostaglandins in the gastric mucosa by 60%.
The endoscopic examinations performed after 6 and 12 weeks of treatment revealed superficial mucosal lesions, and in one patient the appearance of a gastric ulcer (5) . This toxicity has been confirmed in controlled prospective studies evaluating the efficacy of longterm aspirin in the prevention of thrombotic vascular disease (6, 7, 8) . On the other hand, Weil et al. (2) demonstrated in a case-control study that the risk of bleeding ulcer was dose -dependent, multiplied respectively by 2.3, 3.2, and 3.9, for daily doses of 75, 150, and 325 mg of aspirin. The risk of hemorrhage associated with low-dose aspirin is aggravated in the case of concomitant use of non-selective NSAID (9) . Selective COX2 inhibitors, therefore, appear theoretically as the ideal anti-inflammatory treatment in patients with cardiovascular risk who receive lowdose aspirin. Unexpectedly, it has been reported that the risk of ulcerative complications in patients receiving chronic low-dose aspirin therapy treated with celecoxib was not significantly different from that seen in non-selective NSAID associated to aspirin (10) . Experimental studies in rats suggest that inhibition of COX2 may significantly aggravate the deleterious effect of COX1 inhibition on the gastric mucosa (11) . Pending complementary clinical studies, the association of low-dose aspirin-selective COX2 inhibitors should be considered as a hazardous association justifying the need of a preventive treatment.
COCLUSION
In this study on patients with low-dose aspirin for the prevention of cardiovascular effects and UGB: the female sex is predominant as well as advanced age; The history of digestive disorders, gastroduodenal ulcer or UGB, harmful habits (alcoholism, smoking ...) and the concomitant use of certain drugs (NSAID, anticoagulants) are the main risk factors for the occurrence of UGB. These factors are associated in 22.4% of the cases. Severe UGB occurred in 54, 5% of the cases; Duodenal ulcer (32.9%) and gastric ulcer (29%) are the most frequent endoscopic lesions; and stages 3 and 4 are the most frequent (71%) of the Lanza classification. We concluded that UGB and mucosal lesions are more severe in patients with lowdose aspirin.
